Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIA
Ozanimod demonstrated continued efficacy over 96 weeks on MRI and clinical m...
2016-09-20
文传商讯
Takeda Receives Positive CHMP Opinion for Conditional Approval of NINLA
− If authorized, NINLARO will provide a new treatment option for Europ...
2016-09-20
文传商讯
New analysis showed dose adjustment of Giotrif (afatinib) improved tole
A new analysis from two Phase III trials published in Annals of Oncology sho...
2016-09-09
文传商讯
New long-term data demonstrates continued safety and beneficial effect
Interim data suggest long-term benefit with consistent yearly changes in for...
2016-09-09
文传商讯
Takeda Launches Largest Pharmaceutical Company-Sponsored Global Observa
Open-source, collaborative study initiated to advance understanding of real-...
2016-09-02
文传商讯
ESC Congress 2016 Late Breaking Science Registry Latest data on dabigat
First results from GLORIA™-AF Registry Program: Low incidences of stro...
2016-08-31
文传商讯
Boehringer Ingelheim launches RE-VECTO global program to capture data o
Praxbind® (idarucizumab) is the specific reversal agent for the oral ant...
2016-08-16
文传商讯
Takeda Receives Marketing Authorization in Canada for NINLARO (ixazomib
-NINLARO is the first and only oral proteasome inhibitor approved to provide...
2016-08-09
文传商讯
The European Stroke Organisation and Boehringer Ingelheim launch the “
The Angels Initiative aims to build a community of at least 1,500 stroke cen...
2016-07-21
文传商讯
Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in
• Study to evaluate potential of novel combination therapy for hormone ...
2016-07-15
文传商讯
